Novartis AG

The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape (2017) Goebell P, Doehn C, Gruellich C, Gruenwald V, Steiner T, Ehness R, Welslau M Journal article The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) randomized controlled trial: design and methods (2017) Landi F, Cesari M, Calvani R, Cherubini A, Di Bari M, Bejuit R, Mshid J, et al. Journal article Interim results from PAZOREAL: A non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape (2017) Bedke J, Welslau M, Boegemann M, Schostak M, Hering-Schubert C, Petzoldt A, Wolf T, et al. Conference contribution H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE study (2017) Maurer M, Staubach P, Raap U, Richter-Huhn G, Bauer A, Rueff F, Jakob T, et al. Journal article Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4 (2017) Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, et al. Journal article SECUKINUMAB PROVIDES RAPID AND SUSTAINED PAIN RELIEF IN PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE FUTURE 2 STUDY (2017) Mcinnes IB, Mease PJ, Schett G, Kirkham B, Strand V, Williams N, Fox T, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 3-YEAR EFFICACY AND SAFETY RESULTS FROM PHASE 3 FUTURE 1 TRIAL (2017) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS (PSA) THROUGH 3 YEARS: EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL (2017) Hall S, Mease P, Kavanaugh A, Reimold A, Tahir H, Rech J, Geusens P, et al. Conference contribution Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 2-year efficacy and safety results from the phase 3 randomised, double-blind, placebo-controlled trial FUTURE 1 (2017) Rech J, Reinhardt M, Kavanaugh A, Geusens P, Mpofu S Conference contribution Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors (2017) Doerffel Y, Kullmann F, Lammert F, Quietzsch D, Schöfl C, Schuppert F, Weber M, et al. Conference contribution